Takeda Pharmaceutical Company Limited
TAKWI
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.85B | 29.62B | 29.99B | 30.08B | 30.24B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.85B | 29.62B | 29.99B | 30.08B | 30.24B |
| Cost of Revenue | 10.29B | 10.42B | 10.50B | 10.32B | 10.48B |
| Gross Profit | 19.56B | 19.20B | 19.49B | 19.76B | 19.77B |
| SG&A Expenses | 7.27B | 7.21B | 7.29B | 7.25B | 7.23B |
| Depreciation & Amortization | 3.57B | 3.56B | 3.61B | 3.60B | 3.60B |
| Other Operating Expenses | -12.20M | 471.16M | 63.72M | 364.46M | 248.59M |
| Total Operating Expenses | 25.76B | 26.29B | 26.17B | 26.33B | 26.25B |
| Operating Income | 4.09B | 3.33B | 3.82B | 3.75B | 3.99B |
| Income Before Tax | 1.40B | 703.04M | 1.32B | 1.15B | 1.53B |
| Income Tax Expenses | 620.97M | 442.33M | 355.19M | 437.74M | 165.33M |
| Earnings from Continuing Operations | 777.52 | 260.71 | 959.94 | 710.88 | 1.37K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.72M | -1.41M | -1.34M | -1.41M | -1.20M |
| Net Income | 775.80M | 259.30M | 958.61M | 709.46M | 1.37B |
| EBIT | 4.09B | 3.33B | 3.82B | 3.75B | 3.99B |
| EBITDA | 8.49B | 7.72B | 8.24B | 8.15B | 8.44B |
| EPS Basic | 0.50 | 0.17 | 0.61 | 0.45 | 0.87 |
| Normalized Basic EPS | 1.32 | 0.91 | 1.08 | 1.07 | 1.18 |
| EPS Diluted | 0.48 | 0.16 | 0.60 | 0.44 | 0.85 |
| Normalized Diluted EPS | 1.31 | 0.90 | 1.07 | 1.06 | 1.17 |
| Average Basic Shares Outstanding | 6.30B | 6.31B | 6.31B | 6.32B | 6.31B |
| Average Diluted Shares Outstanding | 6.35B | 6.33B | 6.36B | 6.37B | 6.35B |
| Dividend Per Share | 1.32 | 1.32 | 1.30 | 1.30 | 1.29 |
| Payout Ratio | 270.24% | 803.40% | 217.56% | 277.06% | 143.72% |